Mersana Therapeutics, Inc. (MRSN)

NASDAQ: MRSN · IEX Real-Time Price · USD
4.270
+0.210 (5.17%)
At close: Feb 27, 2024, 4:00 PM
4.380
+0.110 (2.58%)
Pre-market: Feb 28, 2024, 4:59 AM EST
5.17%
Market Cap 520.31M
Revenue (ttm) 40.84M
Net Income (ttm) -197.05M
Shares Out 120.58M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,229,046
Open 4.100
Previous Close 4.060
Day's Range 4.000 - 4.345
52-Week Range 0.801 - 9.620
Beta 1.37
Analysts Buy
Price Target 4.67 (+9.37%)
Earnings Date Feb 28, 2024

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Ther... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2017
Employees 228
Stock Exchange NASDAQ
Ticker Symbol MRSN
Full Company Profile

Financial Performance

In 2022, MRSN's revenue was $26.58 million, an increase of 61716.28% compared to the previous year's $43,000. Losses were -$204.21 million, 20.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $4.67, which is an increase of 9.37% from the latest price.

Price Target
$4.67
(9.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

21 hours ago - GlobeNewsWire

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

6 days ago - GlobeNewsWire

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

26 days ago - GlobeNewsWire

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

7 weeks ago - GlobeNewsWire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

3 months ago - GlobeNewsWire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

4 months ago - GlobeNewsWire

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

4 months ago - GlobeNewsWire

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

4 months ago - GlobeNewsWire

Mersana Therapeutics Announces Changes in Leadership

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such investors are advi...

6 months ago - PRNewsWire

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

7 months ago - GlobeNewsWire

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

7 months ago - GlobeNewsWire

MRSN FRAUD ALERT: Jakubowitz Law is Investigating Mersana Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Mersana Therapeutics, Inc...

8 months ago - PRNewsWire

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) violated federal securities laws. ...

8 months ago - PRNewsWire

MRSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

NEW YORK , June 26, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into...

8 months ago - PRNewsWire

MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

NEW YORK , June 22, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into...

8 months ago - PRNewsWire

MRSN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

NEW YORK , June 21, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) concerning possible violati...

8 months ago - PRNewsWire

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

Mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its ovarian cancer drug studies and paused patient enrollment, citing safety co...

9 months ago - Reuters

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

Mersana Therapeutics Inc.'s stock MRSN cratered 73% premarket Thursday, after the company announced that the U.S. Food and Drug Administration had placed a partial clinical hold on two trials of a tre...

9 months ago - Market Watch

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

9 months ago - GlobeNewsWire

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

9 months ago - GlobeNewsWire

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

10 months ago - GlobeNewsWire

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

10 months ago - GlobeNewsWire

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

10 months ago - GlobeNewsWire

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

10 months ago - GlobeNewsWire